Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Soiken HoldingsTSE:2385 +2.29%58 EV-to-EBIT is 0.61 as of Aug. 17, 2026, which is 93% below its 10-year median of 8.15. GuruFocus rates TSE:2385 with a GF Score™ of 58/100 and a GF Value™ of 円118.65 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 370 Biotechnology companies, Soiken Holdings ranks better than 83.24% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Soiken Holdings's Enterprise Value for the quarter that ended in Dec. 2025 was 円824 Mil.
Soiken Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円312 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Soiken Holdings EV-to-EBIT Related Terms
Soiken Holdings EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Soiken Holdings's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2385 vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Soiken Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Soiken Holdings EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Soiken Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Soiken Holdings's EV-to-EBIT falls into.
Soiken Holdings's current Enterprise Value is 円189 Mil.
Soiken Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円312 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Soiken Holdings (TSE:2385) has a EV-to-EBIT of 0.61 as of Aug. 17, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Soiken Holdings and its competitors. This is 93% below median its historical median of 8.15. According to the industry distribution chart, Soiken Holdings ranks #62 out of 370 companies in the Biotechnology industry, placing it in the top 16.8%.
Is Soiken Holdings' EV-to-EBIT too high?
Soiken Holdings' current EV-to-EBIT of 0.61 is 93% below median its 10-year median of 8.15. The Biotechnology industry median EV-to-EBIT is 16.28. Soiken Holdings' value of 0.61 is 96.3% below this industry median. Based on the distribution chart, Soiken Holdings ranks #62 out of 370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Soiken Holdings has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Soiken Holdings' EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Soiken Holdings ranks #62 out of 370 companies for EV-to-EBIT. This places Soiken Holdings in the top 17% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 16.28. Soiken Holdings' value of 0.61 is 96.3% below this benchmark. While the company's 10-year median is 8.15 vs. the industry median of 16.28, Soiken Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.28, based on 370 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Soiken Holdings's current EV-to-EBIT of 0.61 is 96.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Soiken Holdings and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Soiken Holdings's current EV-to-EBIT is 0.61, which is 93% below median its own 10-year median of 8.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Soiken Holdings stock overvalued right now?
Based on GuruFocus' analysis, Soiken Holdings (TSE:2385) is currently considered Significantly Overvalued. The stock's GF Value™ is 円118.65, compared to a current price of 円223.00 — trading 87.9% above its estimated fair value. The current EV-to-EBIT is 0.61, which is 93% below median its 10-year median of 8.15 and 96.3% below the Biotechnology industry median of 16.28. Soiken Holdings' overall GF Score™ is 58/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Soiken Holdings (TSE:2385), the current EV-to-EBIT is 0.61 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Soiken Holdings (TSE:2385) Overvalued in 2026?
Based on GuruFocus' analysis, Soiken Holdings stock appears to be overvalued.
The current stock price of 円223.00 is trading 87.9% above its estimated GF Value™ of 円118.65.
GuruFocus considers Soiken Holdings to be Significantly Overvalued.
Key valuation signals for TSE:2385:
EV-to-EBIT: 0.61 (93% below median its 10-year median of 8.15)
GF Value™: 円118.65 vs. price of 円223.00 (87.9% above fair value)
Industry Position: 96.3% below the Biotechnology median (#62 of 370)
No single metric tells the full story. See the TSE:2385 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Soiken Holdings Inc operates as a biotechnology company in Japan. It provides clinical testing for pharmaceutical and food manufacturers that develop drugs and health food products based on biomarkers. It is involved in the marketing research and post-marketing surveillance of health supplements.
58GF Score
Get the complete analysis for TSE:2385
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2385 has been successfully added to your 
